6-氯-3-甲氧基-4-吡嗪胺 | 14369-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 6-氯-3-甲氧基-4-吡嗪胺
• 英文名称: 4-amino-6-chloro-3-methoxypyridazine
• 英文别名: 6-chloro-3-methoxy-pyridazin-4-amine；6-Chloro-3-methoxypyridazin-4-amine
• CAS: 14369-14-3
• 化学式: C₅H₆ClN₃O
• 分子量: 159.575
• InChiKey: NDPRYUWUIMNDNC-UHFFFAOYSA-N

物化性质

• 熔点：
  190-191 °C
• 沸点：
  373.5±37.0 °C(Predicted)
• 密度：
  1.398±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Chloro-3-methoxypyridazin-4-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloro-3-methoxypyridazin-4-amine
CAS number: 14369-14-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H6ClN3O
Molecular weight: 159.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氯-3-甲氧基-4-吡嗪胺 在 4-二甲氨基吡啶 、 ruthenium trichloride 、 sodium tetrahydroborate 、 四(三苯基膦)钯 、 四溴化碳 、 N-甲基吗啉氧化物 、 三乙胺 、 三苯基膦 、 copper(l) chloride 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 tert-butyl N-[6-(bromomethyl)-3-methoxy-pyridazin-4-yl]carbamate
  参考文献：
  名称：

  [EN] TYK2 INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS

  摘要：

  本发明描述了用于治疗TYK2介导的疾病的化合物。在某些实施方式中，TYK2介导的疾病是一种自身免疫性疾病、炎症性疾病、增殖性疾病、内分泌疾病、神经疾病或与移植相关的疾病。

  公开号：

  WO2020185755A1
• 作为产物：
  描述：

  4-azido-6-chloro-3-methoxypyridazine 在 哌啶 、 硫化氢 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以40%的产率得到6-氯-3-甲氧基-4-吡嗪胺
  参考文献：
  名称：

  A New Route to Aminodiazines via Metalation Reaction. Synthesis of an Aza Analogue of Nevirapine: Diazines XV

  摘要：

  报道了一种合成氨基二嗪的新路线，使用了二嗪的邻位定向锂化，随后与作为电亲体的托烯基叠氮化物反应。对所获得的叠氮或四唑化合物进行了还原，得到了预期的胺。这种方法学使得新氨基二嗪的合成成为可能，并提高了之前描述的各种氨基二嗪的产率。该反应被用于制备 Nevirapine 的氮杂类似物。

  DOI：

  10.1055/s-1996-4303

文献信息

• [EN] PYRIDAZINIL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS<br/>[FR] DERIVES DE PYRIDAZINILE QUINAZOLINE POUR LE TRAITEMENT DE TUMEURS
  申请人：ASTRAZENECA AB

  公开号：WO2004108707A1

  公开（公告）日：2004-12-16

  The invention concerns quinazoline derivatives of Formula (I) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)(R3) group wherein each R2 or R3 group is hydrogen or (1-8C)alkyl, m is 1, 2 or 3, each R1 group has any of the meanings defined in the description, Ra is halogeno or (1-6C)alkoxy, Rb is halogeno or (1-6C)alkoxy, and Rc is hydrogen, halogeno, (1-8C)alkyl or (1-6C)alkoxy, or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

  该发明涉及配方（I）的喹唑啉衍生物，其中Z是O、S、SO、SO2、N（R2）或C（R2）（R3）基团，其中每个R2或R3基团是氢或（1-8C）烷基，m为1、2或3，每个R1基团具有描述中定义的任何含义，Ra是卤代或（1-6C）烷氧基，Rb是卤代或（1-6C）烷氧基，Rc是氢、卤代、（1-8C）烷基或（1-6C）烷氧基，或其药用盐；它们的制备方法，含有它们的药物组合物以及它们在制造用作抗侵袭剂治疗和/或治疗固体肿瘤疾病的药物的用途。
• Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
  申请人：Amgen Inc.

  公开号：US20030096819A1

  公开（公告）日：2003-05-22

  The present invention comprises a new class of novel aryl and heteroaryl substituted fused pyrrole compounds useful for the prophylaxis and treatment of diseases or conditions, such as TNF-&agr;, IL-1&bgr; , IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of inflammation and other maladies, such as pain and diabetes, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  本发明涉及一类新型的芳基和杂环芳基取代融合吡咯化合物，用于预防和治疗疾病或病症，例如TNF-α，IL-1β，IL-6和/或IL-8介导的疾病，以及其他疾病，如疼痛和糖尿病。特别地，本发明的化合物用于预防和治疗涉及炎症的疾病或病症。因此，本发明还包括包含本发明的化合物的制药组合物，使用本发明的化合物和组合物预防和治疗炎症和其他疾病或病症的方法，以及用于制备本发明化合物的中间体和过程。本发明还涉及制备这种化合物的过程以及在这些过程中有用的中间体。
• Fused Thiazole Derivatives as Kinase Inhibitors
  申请人：Alexander Rikki Peter

  公开号：US20100137302A1

  公开（公告）日：2010-06-03

  A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

  一系列6,7-二氢[1,3]噻唑并[5,4-c]吡啶-4(5H)-酮衍生物及其类似物，其在2位被一个可选择取代的吗啡啶-4-基团取代，是PI3激酶酶的选择性抑制剂，在医学上具有益处，例如用于治疗炎症、自身免疫、心血管、神经退行性、代谢、肿瘤、疼痛或眼科疾病。
• [EN] POLO LIKE KINASE 4 INHIBITORS<br/>[FR] INHIBITEURS DE KINASE DE TYPE POLO 4
  申请人：ORIC PHARMACEUTICALS INC

  公开号：WO2022240876A1

  公开（公告）日：2022-11-17

  Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Formula (I)

  本文披露了公式（I）的化合物或其药学上可接受的盐，它们是Polo Like Kinase 4（PLK4）的抑制剂。本文还披露了包含公式（I）的化合物或其药学上可接受的盐以及一个或多个药学上可接受的辅料的制药组合物。本文还披露了治疗需要的患者的癌症的方法，包括向患者投与公式（I）的化合物或其药学上可接受的盐的量。公式（I）:
• 哒嗪类化合物及其制备方法、药物组合物和应用
  申请人：中国药科大学

  公开号：CN118005615A

  公开（公告）日：2024-05-10

  本发明公开了一种哒嗪类化合物及其制备方法、药物组合物和应用。该类化合物结构如式I所示，还包含其立体异构体、内消旋体、外消旋体、前药、结晶、药学上可接受的盐或它们的混合物。本发明设计的化合物对CD73具有显著的抑制作用，并且具有良好的药代谢动力学性质，可以通过免疫调节作用实现治疗效果，因此可以广泛应用在制备预防和/或治疗CD73介导的或依赖的疾病或病症的药物的制备中，同时化合物制备方法利于结构拓展。#imgabs0#